ARFGAP1

Across TCGA pan-cancer cohorts, ARFGAP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARFGAP1 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARFGAP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARFGAP1 expression acts as an unfavorable survival marker, although some lineages such as COAD and GBM show a favorable association.

CCRCC, LSCC, and COAD are the cancer types where ARFGAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.374	0.767	.001	36	view →
LSCC	DFS	Tertile	II,III,IV	0.697	0.945	.005	18	view →
COAD	DFS	Tertile	All	1.000	0.872	.046	12	view →
LUAD	DFS	Quartile	All	0.400	0.803	.005	3	view →
GBM	DFS	Median	All	0.801	0.639	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARFGAP1–CCRCC (DFS)

Open the CCRCC breakdown →